You are here

Prostate Test Found to Save Few Lives

March 18, 2009 -- The PSA blood test, used to screen for prostate cancer, saves few lives and leads to risky and unnecessary treatments for large numbers of men, two large studies have found.

In two large randomized trials, one in the United States and the other in Europe, researchers examined the effect of annual prostate-specific–antigen (PSA) screening on the rate of death from prostate cancer and found that it was small and was offset by false positive diagnoses. In a roundtable discussion moderated by Dr. Thomas Lee, oncologist Philip Kantoff and primary care physician Mary McNaughton-Collins debate the clinical implications of the new findings and the best way to advise patients about undergoing PSA testing.

Read the U.S. Study, the European study, and the accompanying editorial. View the video roundtable.

Source: New England Journal of Medicine

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks